SIGA Technologies, Inc. (SIGA) SEC Filings & Earnings Calls

Mpox label restriction

“CHMP recommended that the product no longer be used for the treatment of mpox, and on May 29, 2026, the European Commission adopted the opinion of the CHMP.”

Revenue concentration on U.S. government

“Revenue decline driven by lower U.S. government orders for oral TPOXX; company is dependent on BARDA contracts.”

Tariff exposure for IV TPOXX

“With respect to IV TPOXX®, tariff activity or other trading restrictions involving the U.S. and Europe may materially increase raw material costs for IV TPOXX® and, in turn, may materially increase IV TPOXX® overall manufacturing costs.” · word for word

Dependence on US government contracts; 19C contract completed, renewal uncertain.

“These deliveries completed the last procurement order under the 19C contract.” · word for word

Revenue concentration in single product TPOXX; no other revenue sources.

“All product sales are TPOXX; no other products mentioned.”

Significant increase in authorized shares may lead to shareholder dilution.

“increase the aggregate number of shares of the Company’s common stock... by 6,500,000 shares”

Significant decline in product sales and widening losses indicate revenue volatility and cost pressure.

“Product sales down from $5.8M to $3.5M; net loss increased from $0.4M to $3.5M”

Dependence on single government contract

“the risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms” · word for word

Clinical trial failure for mpox indication

“the PALM 007 study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution” · word for word

Tariff exposure on IV TPOXX manufacturing

“tariff activity or other trading restrictions involving the U.S. and Europe may materially increase raw material costs for IV TPOXX®” · word for word

No international sales in Q1 2026

“In the three months ended March 31, 2026, the Company did not have international sales.” · word for word

Revenue decline from prior year; dependence on government contracts and regulatory outcomes.

“Product sales down from $133.3M to $88M; CHMP referral for tecovirimat mpox indication.”

Customer Concentration

“Revenues from product sales and supportive services for the years ended December 31, 2025 and 2024 were $88.0 million and $133.3 million, respectively. Such revenues for the year ended December 31, 2025 include $53.3 million of oral TPOXX® sales and $25.8 million of IV TPOXX® sales to the U.S. Government under the 19C BARDA Contract.” · word for word

Revenue Decline

“Revenues from product sales and supportive services for the years ended December 31, 2025 and 2024 were $88.0 million and $133.3 million, respectively.” · word for word

Revenue concentration on U.S. government contracts; quarterly volatility due to lumpy procurement.

“Q3 product sales $0.9M vs $8.9M prior year; nine-month product sales $85.8M driven by SNS deliveries.”

Dependence on BARDA contract modifications and international market development.

“BARDA 19C contract modifications added $27M; international market still nascent.”

EMA Referral Procedure

“On July 24, 2025, the EMA’s Committee for Medicinal Products for Human Use closed its third annual reassessment for Tecovirimat-SIGA and initiated a referral procedure for the product following questions over its effectiveness in the treatment of mpox.” · word for word

Revenue Concentration on U.S. Government

“For the nine months ended September 30, 2025, revenues from product sales and supportive services were $85.8 million. Such revenues include $53.3 million of oral TPOXX® and $25.8 million of IV TPOXX® sales to the U.S. Government under the 19C BARDA Contract.” · word for word

Tariff Exposure for IV TPOXX

“tariff activity involving the U.S. and Europe may materially increase raw material costs for IV TPOXX® and, in turn, may materially increase IV TPOXX® overall manufacturing costs.” · word for word